Hoth Therapeutics Inc (HOTH)

$1.19 +0.01 (0.85%)
Market Cap 15.65M
Revenue (ttm) 0.00
Net Income (ttm) -8.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 130,200
Avg Vol 971,596
Day's Range N/A - N/A
Shares Out 13.26M
Stochastic %K 19%
Beta 0.63
Analysts Strong Sell
Price Target $4.50

Company Profile

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for th...

Industry: Biotechnology
Sector: Healthcare
Phone: (646) 756-2997
Address:
1177 Avenue of the Americas, Suite 5066 5th Floor, New York, United States
MahiMe
MahiMe Nov. 14 at 8:27 PM
$HOTH 13 institutional owners have filed 13F forms with the Securities Exchange Commission (SEC) today... https://fintel.io/so/us/hoth
1 · Reply
Alexander_Willingham_III
Alexander_Willingham_III Nov. 14 at 6:03 PM
$HOTH "We believe that our existing cash as of September 30, 2025 will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date that our unaudited condensed consolidated financial statements are available to be issued." "Cash and cash equivalents $ 7,847,911"
0 · Reply
Alexander_Willingham_III
Alexander_Willingham_III Nov. 14 at 6:16 AM
$HOTH Also one of the deals of the year! BUY
0 · Reply
RaphaelRapoport
RaphaelRapoport Nov. 13 at 10:05 PM
$HOTH The did an ATM at $2.07 and increased total float by 25% so a fair price at that 25% reduction would be 1.55. I think we're heavily undervalued right now and expect this to go up when markets stabilize. This is amazing buying opportunity.
1 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Nov. 13 at 6:15 PM
$HOTH like clockwork they do an offering the next day. What a scumbag company. Whoever is actually here vs the bots , bend over.
3 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Nov. 13 at 4:49 AM
$HOTH ah i see Robb knie still scamming people for a 600K salary. Are the two married people still on the BOD with him? Scumbag team
0 · Reply
RaphaelRapoport
RaphaelRapoport Nov. 12 at 9:47 PM
$HOTH https://www.sec.gov/ix?doc=/Archives/edgar/data/1711786/000121390025109220/ea0262611-10q_hoth.htm 10Q shared- Will read and post my sentiment and any key highlights
1 · Reply
Tino321
Tino321 Nov. 11 at 9:12 PM
$HOTH we need a move like $LFS 🙂‍↕️
0 · Reply
Tino321
Tino321 Nov. 11 at 3:13 AM
$HOTH remember we just have to be right once. I think this is the one folks. Lot of potential for at least 2-3x 🤙. 🎰
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 9:00 PM
$HOTH UPDATE PENDING CHANGING IT FOR NOW
0 · Reply
Latest News on HOTH
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Oct 27, 2025, 7:49 AM EDT - 18 days ago

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Oct 21, 2025, 8:23 AM EDT - 24 days ago

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Oct 8, 2025, 8:02 AM EDT - 5 weeks ago

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Oct 7, 2025, 7:57 AM EDT - 5 weeks ago

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Sep 24, 2025, 8:13 AM EDT - 7 weeks ago

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History

Sep 16, 2025, 8:14 AM EDT - 2 months ago

Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Sep 10, 2025, 8:29 AM EDT - 2 months ago

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Sep 4, 2025, 8:16 AM EDT - 2 months ago

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

Sep 2, 2025, 8:16 AM EDT - 2 months ago

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

Jul 29, 2025, 7:58 AM EDT - 3 months ago

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Jul 22, 2025, 8:19 AM EDT - 4 months ago

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Jun 25, 2025, 8:27 AM EDT - 5 months ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

SILO

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Jun 24, 2025, 10:36 AM EDT - 5 months ago

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Jun 23, 2025, 8:03 AM EDT - 5 months ago

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Jun 18, 2025, 1:34 PM EDT - 5 months ago

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Jun 18, 2025, 8:22 AM EDT - 5 months ago

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Hoth Therapeutics to Attend 2025 BIO International Convention

Jun 16, 2025, 8:00 AM EDT - 5 months ago

Hoth Therapeutics to Attend 2025 BIO International Convention

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Jun 12, 2025, 9:17 AM EDT - 5 months ago

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Jun 11, 2025, 8:28 AM EDT - 5 months ago

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Jun 5, 2025, 8:12 AM EDT - 5 months ago

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

May 12, 2025, 7:30 AM EDT - 6 months ago

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Apr 17, 2025, 8:01 AM EDT - 7 months ago

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Apr 15, 2025, 8:19 AM EDT - 7 months ago

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Apr 2, 2025, 8:02 AM EDT - 8 months ago

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Apr 2, 2025, 7:58 AM EDT - 8 months ago

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Mar 31, 2025, 4:45 PM EDT - 8 months ago

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Mar 26, 2025, 8:02 AM EDT - 8 months ago

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Mar 18, 2025, 8:06 AM EDT - 8 months ago

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Mar 10, 2025, 8:02 AM EDT - 8 months ago

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Mar 5, 2025, 1:40 PM EST - 9 months ago

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Mar 4, 2025, 8:16 AM EST - 9 months ago

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Feb 10, 2025, 8:22 AM EST - 9 months ago

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jan 24, 2025, 8:29 AM EST - 10 months ago

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Jan 21, 2025, 8:29 AM EST - 10 months ago

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Jan 17, 2025, 8:29 AM EST - 10 months ago

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Jan 8, 2025, 1:27 PM EST - 11 months ago

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

Jan 7, 2025, 11:53 AM EST - 11 months ago

Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Jan 7, 2025, 8:29 AM EST - 11 months ago

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Dec 26, 2024, 7:58 AM EST - 11 months ago

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

Nov 20, 2024, 7:38 AM EST - 1 year ago

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Oct 29, 2024, 12:43 PM EDT - 1 year ago

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Oct 15, 2024, 6:38 AM EDT - 1 year ago

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Sep 17, 2024, 7:57 AM EDT - 1 year ago

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Sep 5, 2024, 10:32 AM EDT - 1 year ago

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Sep 5, 2024, 8:03 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Aug 15, 2024, 8:04 AM EDT - 1 year ago

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Jul 16, 2024, 8:31 AM EDT - 1 year ago

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Jun 10, 2024, 8:11 AM EDT - 1 year ago

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

May 1, 2024, 8:00 AM EDT - 1 year ago

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

MahiMe
MahiMe Nov. 14 at 8:27 PM
$HOTH 13 institutional owners have filed 13F forms with the Securities Exchange Commission (SEC) today... https://fintel.io/so/us/hoth
1 · Reply
Alexander_Willingham_III
Alexander_Willingham_III Nov. 14 at 6:03 PM
$HOTH "We believe that our existing cash as of September 30, 2025 will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date that our unaudited condensed consolidated financial statements are available to be issued." "Cash and cash equivalents $ 7,847,911"
0 · Reply
Alexander_Willingham_III
Alexander_Willingham_III Nov. 14 at 6:16 AM
$HOTH Also one of the deals of the year! BUY
0 · Reply
RaphaelRapoport
RaphaelRapoport Nov. 13 at 10:05 PM
$HOTH The did an ATM at $2.07 and increased total float by 25% so a fair price at that 25% reduction would be 1.55. I think we're heavily undervalued right now and expect this to go up when markets stabilize. This is amazing buying opportunity.
1 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Nov. 13 at 6:15 PM
$HOTH like clockwork they do an offering the next day. What a scumbag company. Whoever is actually here vs the bots , bend over.
3 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Nov. 13 at 4:49 AM
$HOTH ah i see Robb knie still scamming people for a 600K salary. Are the two married people still on the BOD with him? Scumbag team
0 · Reply
RaphaelRapoport
RaphaelRapoport Nov. 12 at 9:47 PM
$HOTH https://www.sec.gov/ix?doc=/Archives/edgar/data/1711786/000121390025109220/ea0262611-10q_hoth.htm 10Q shared- Will read and post my sentiment and any key highlights
1 · Reply
Tino321
Tino321 Nov. 11 at 9:12 PM
$HOTH we need a move like $LFS 🙂‍↕️
0 · Reply
Tino321
Tino321 Nov. 11 at 3:13 AM
$HOTH remember we just have to be right once. I think this is the one folks. Lot of potential for at least 2-3x 🤙. 🎰
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 9:00 PM
$HOTH UPDATE PENDING CHANGING IT FOR NOW
0 · Reply
MahiMe
MahiMe Nov. 10 at 8:36 PM
$HOTH A new Lancet study projects that by 2050, over 3.8 billion adults and 746 million children could be affected by obesity and overweight. We're developing HT-VA, a GDNF-based therapy targeting obesity and related conditions. https://x.com/HothInc/status/1987921723316945058?t=UtfReEuZJ8NAmCW2i-2fKg&s=19
0 · Reply
SPYmyQQQ
SPYmyQQQ Nov. 10 at 5:03 PM
🚀 New Signal ✅ 💊 $HOTH 🗓️ Nov 10, 2025 💵 Entry: $1.23 🎯 Target (Opt.): $1.47 (+19.51%) 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
SPYmyQQQ
SPYmyQQQ Nov. 10 at 5:03 PM
🚀 New Signal ✅ 🪙 $HOTH 🗓️ Nov 10, 2025 💵 Entry: $1.23 🎯 Target (Opt.): $1.43 (+16.26%) 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 1:06 PM
$HOTH using your H 1st n 4th H's crossing for market as a whole ! $VRAR R's 2nd n 4th R positions using $GORV R from Gorv 3rd position only 1 R merging fusing to allow the V for gorv last 4th position $PSTV V beloved coding
0 · Reply
Black_Jobs
Black_Jobs Nov. 7 at 5:06 PM
$HOTH Drops on absolutely ZERO news.. This is one of the best stocks out there with a bright future and it goes down for no reason?
0 · Reply
Raaayed
Raaayed Nov. 6 at 9:56 PM
$HOTH
0 · Reply
Alexander_Willingham_III
Alexander_Willingham_III Nov. 6 at 5:55 AM
$GPUS $RKT $HOTH $JBLU These 4 names are HEAVILY undervalued! Buy and hold, asap. 📈 Sizable gains are coming...
0 · Reply
WallStreetReporter
WallStreetReporter Nov. 4 at 2:20 PM
$HOTH
0 · Reply
Tino321
Tino321 Nov. 3 at 7:06 AM
$HOTH let’s get to 2$ this week
0 · Reply
RaphaelRapoport
RaphaelRapoport Nov. 2 at 11:48 PM
$HOTH Let's go. news on news on news.
0 · Reply
Theflash88
Theflash88 Oct. 31 at 8:45 PM
$HOTH
1 · Reply
Titaniumjelly
Titaniumjelly Oct. 31 at 7:56 PM
$HOTH MACD is likely going to cross into green on 1yr 1day chart, maybe on Tuesday. Maybe Monday.
1 · Reply